Presbia PLC

Presbia — Investor Presentation (September 2016)

23 slides from Presbia's investor presentation, Sep 7, 2016

  1. Slide 1: September 2016 Investor Presentation

    September 2016 Investor Presentation NASDAQ: LENS Exhibit 99.1

  2. Slide 2: Disclosure

    Disclosure To the extent statements contained in this presentation are not descriptions of historical facts regarding Presbia PLC and its subsidiaries (collectively “Presbia,” “we,” “us,” or “our”), they are forward-looking statements reflecting management’s current beliefs and expectations. Forward

  3. Slide 3: Introduction

    Presbyopia is an age related visual impairment effecting near field vision. It’s what causes us to need reading glasses as we enter middle age One of the largest and most under-served ophthalmic markets, (1.8B afflicted) The Presbia Flexivue Microlens is a best in class treatment option for presbyop

  4. Slide 4: The Presbia Procedure

    - A True “Microlens” with 3.2 mm diameter and edge thickness of 0.015 mm - Hydrophilic acrylic material similar to that used in IOLs for > 20 years - Offered in a wide range of powers ranging from +1.5 diopter to +3.5 diopter, in 0.25 diopter increments -Invisible to the naked eye once implanted -Ca

  5. Slide 5: Market Opportunity

    Market Opportunity Presbyopia is one of the largest and most under served ophthalmic markets; Corneal inlays are an exciting surgical treatment for presbyopia LASIK is a market benchmark Shows rapid commercial acceptance of a cash pay medical procedure to eliminate glasses LASIK corrects distance vi

  6. Slide 6: Competitive Landscape

    Competitive Landscape Corneal inlays are an exciting surgical treatment for presbyopia There are two primary competitors in the corneal inlay space AcuFocus - KAMRA Non-powered “disc” implanted in the non-dominant eye Utilizes the “pinhole effect” to focus light to enhance near vision Not easily rev

  7. Slide 7: The Physician Perspective

    The Physician Perspective Flat-to-declining LASIK procedure volumes, overcapacity, and LASIK procedure price erosion Highly receptive to new private pay presbyopia procedure requiring no capital outlay Refractive Surgery Centers No capital expenditure required Simple surgical procedure, short learni

  8. Slide 8: 6-Month Interim Data

    6-Month Interim Data Subjects gained an average of 5 lines of uncorrected near visual acuity (the ability to see close objects without prescription enhancement) in treated eyes For example, an improvement from reading a subhead in the news paper (12pt font) to reading the content label (4pt font) on

  9. Slide 9: No Change in Binocular Distance Vision

    No Change in Binocular Distance Vision There was little to no change in binocular uncorrected distance vision. Presbia Flexivue Microlens is designed to take advantage of binocular vision as most patients fuse both images in the brain. The brain filters bad images, thus, resulting in accepting the b

  10. Slide 10: FDA Timeline

    Sept 2015: Completion of 2nd stage enrollment (a total of 346 subjects) Throughout 2016 into 2017: Focus is on compliance – constant subject follow through Q4, 2017: Submit clinical data in Final PMA Module to FDA (300 subjects, 2 year data) FDA Timeline 2017 2015 2016 2018 Q1 – Q3, 2018: Anticipate

  11. Slide 11: Focused Commercialization Strategy

    Focused Commercialization Strategy 2016 2017 2018 South Korea (Asia/Pacific Hub) Most penetrated LASIK market in the world Major elective surgery market Many surgeons concentrated geographically Samsung Medical Center clinical validation study Patient awareness campaign, recruitment Centers of Excel

  12. Slide 12: R&D and IP history timeline

    R&D: Corneal inlay for Presbyopia (includes patent) Powered Micro-Lens (patent) Lens with central hole (patent) Surgical method to use corneal pocket (patent) Mechanical equipment for pocket creation Lens inserter (includes patent) First human implants Acquisition of Neoptics/Biovision Intellectual

  13. Slide 13: Comprehensive IP Portfolio

    Comprehensive IP Portfolio Consolidated IP and know how creates a patent protected platform to deploy our micro-lens technology into solutions for vision problems beyond presbyopia The only corneal implant company with global intellectual property for near-vision correction with a powered micro-lens

  14. Slide 14: Additional Materials

    eS. PRESBIA freedom in sight Additional Materials

  15. Slide 15: Leadership Team

    Leadership Team TODD COOPER, PRESIDENT & CEO Todd Cooper has served as the President and Chief Executive Officer of Presbia PLC and as a director of Presbia PLC since January 2015. From July 2011 to November 2014, Mr. Cooper served as the Chief Executive Officer of NVISION, which operates a network

  16. Slide 16: Vladimir Feingold, Chief Technology Officer

    VLADIMIR FEINGOLD, CHIEF TECHNOLOGY OFFICER & EXECUTIVE VICE PRESIDENT Vladimir Feingold has served as the Chief Technology Officer and as a director of Presbia Holdings since September 2009 and has served as the Chief Technology Officer of Presbia PLC since February 2014, an Executive Vice Presiden

  17. Slide 17: Large, Underserved And Growing Market Opportunity

    Large, Underserved And Growing Market Opportunity Projected Demographic-Driven Market Growth 1.8 Billion Presbyopes (billions) Source: 2013 Market Scope. United States (113) Western Europe (128) Latin America (140) China (423) India (249) Rest of World (542) Other Wealthy Nations (53) Japan (58) (mi

  18. Slide 18: A True Microlens

    A True Microlens 1.6 mm Central Zone Diameter Boundary between Central and Optic Zones Shown by Imaginary Line 0.51 mm Central Hole Diameter 3.2 mm Overall Diameter Central Zone Boundary between Central and Optic Zones Shown by Imaginary Line Optic Zone Center Thickness Varies by Lens Power 1.6 mm C

  19. Slide 19: Consistent with the recently reported data

    Consistent with the recently report data

  20. Slide 20: U.S. Pivotal Trial

    U.S. Pivotal Trial Subjects gained an average of 5 lines of uncorrected near visual acuity (the ability to see close objects without enhancement) in treated eyes (Figure A). 82% of subjects achieved 20/40 or better uncorrected distance vision in treated eyes (Figure B). Figure B Figure A Notwithstan

  21. Slide 21: U.S. Pivotal Trial

    U.S. Pivotal Trial 98% of subjects achieved 20/40 or better best corrected distance vision in treated eyes (Figure C) and there was little to no change in binocular best corrected distance vision (Figure D). Figure C Figure D Notwithstanding these results, we cannot assure you when or whether the Co

  22. Slide 22: Manufacturing

    Manufacturing 4,000 square-foot, two-part (wet/dry) manufacturing facility Approved to manufacture devices for U.S. IDE by State of California FDA in 2013 Sufficient capacity to handle projected Presbia Flexivue Microlens™ volume through U.S. launch Approved to manufacture devices for OUS sale by In

  23. Slide 23: Presbia PLC contact details

    Presbia PLC (Headquarters) 120-121 Lower Baggot St. Dublin 2, Ireland tel: +353-1-659-9446 Presbia Coöperatief U.A. Pieter Pauwstraat 2A – I · 1017 ZJ Amsterdam, Netherlands tel: +31-20-7084-556 · fax: +31-20-7084-556 PresbiBio LLC 8845 Irvine Center Dr., Suite 100 · Irvine, CA 92618 tel: +1-949‐502

Presbia — Investor Presentation (September 2016) on 6ix